Post-ASH 2022 iwAL - AML

11 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in AML from ASH 2022

The Post-ASH 2022 iwAL Virtual Workshop was held on 11-12 January 2023, with a packed program covering acute myeloid leukemia (AML) on Day 1, and acute lymphoblastic leukemia (ALL) on Day 2. Both days featured a series of short presentations on selected abstracts from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session.

Venetoclax regimens and combinations Novel targeted or immune therapies Novel therapies FLT3-mutated AML Chemotherapy/targeted therapies Immunotherapies and stem cell transplantation

Session 1: Venetoclax regimens and combinations

Azacitidine, venetoclax & magrolimab in high-risk & R/R AML

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Lintuzumab-Ac225 in combination with intensive chemotherapy in R/R AML

Sameem Abedin Medical College of Wisconsin, Milwaukee, WI, United States

Long-term follow-up of the Phase III VIALE-A clinical trial

Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States

ELN risk stratification & outcomes in patients with AML treated with VEN/AZA

Daniel Pollyea University of Colorado, Denver, CO, United States

Panel discussion

Session 2: Novel targeted or immune therapies

A prospective Phase II study of venetoclax & low dose Ara-C (VALDAC) in AML

Ing Tiong The Alfred Hospital and Monash University, Melbourne, Australia

Venetoclax + CLIA as induction therapy for patients with ND AML & HR-MDS

Tapan Kadia The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Gimema AML1718 part 1: V-FLAI in the induction therapy of non-low-risk AML

Giovanni Marconi Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Panel discussion

Session 3: Novel therapies

Pivekimab sunirine, azacitidine & venetoclax in HR patients with R/R AML

Kendra Sweet H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Revumenib in patients with KMT2A-rearranged or NPM1 mutant AML

Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Phase I/II first-in-human study of ziftomenib in patients with R/R AML

Harry Erba Duke University, Durham, NC, United States

Panel discussion

Session 4: FLT3

FLT3-ITD–specific MRD clearance is associated with improved overall survival

Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States

A sub-analysis of the ALLG INTERVENE study

Chyn Chua The Alfred Hospital and Monash University, Melbourne, Australia

Phase I/II study of azacitidine, venetoclax & gilteritinib for FLT3-mutated AML

Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Panel discussion

Session 5: Chemotherapy/targeted therapies

Genomic correlates of outcome: CPX-351 vs FLAG-Ida in HR AML and MDS

Jad Othman Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Gemtuzumab ozogamicin + intensive chemotherapy in NPM1-mutated AML

Felicitas Thol Hannover Medical School, Hannover, Germany

Panel discussion

Session 6: Immunotherapies and stem cell transplantation

Results from the randomized Phase III ASAP trial

Johannes Schetelig University Hospital TU Dresden, Dresden, Germany

Post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis

Shernan Holtan University of Minnesota, Minneapolis, MN, United States

Enasidenib as maintenance therapy after alloSCT in IDH2-mutated AML

Amandeep Salhotra City of Hope, Duarte, CA, United States

QuANTUM-First: Impact of alloSCT in first CR in addition to quizartinib

Alexander Perl University of Pennsylvania, Philadelphia, PA, United States

Ameli-01: A Phase I trial of UCART123v1.2 in patients with R/R CD123+ AML

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Target densities in malignant & normal cells determine CAR-T cell efficacy

Sascha Haubner Memorial Sloan Kettering Cancer Center, New York City, NY, United States

The race is on: BiTE vs CAR-T as FLT3-directed immunotherapies in AML

Marion Subklewe LMU Hospital Munich, Munich, Germany

Panel discussion

The continued success of the iwAL meeting is in no small part due to the ongoing funding of supporters, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future iwAL meetings and activities, please contact us here.

For the latest updates in AML, visit The AML Channel

Post-ASH 2022 iwAL - AML

Post-ASH 2022 iwAL - AML

Sign-up for our Newsletter!